Stay up to date

News

back to overview
New Spanish clinical data from Proclarix® together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 36th Annual European Urology Congress.

July 6, 2021

University of Naples Federico II is implementing and evaluating Proclarix® to make it available in Italy

May 4, 2021

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

January 14, 2021

Results published of PROPOSe, a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision making in prostate cancer

January 7, 2021

Swiss Center for Laboratory Medicine St. Gallen presents data from Proclarix® at American Association for Clinical Chemistry (AACC) Annual Scientific Meeting

December 10, 2020

University Hospital Frankfurt MVZ GmbH, first laboratory offering Proclarix in Germany

December 2, 2020

Bestätigung der diagnostischen Leistungsfähigkeit des ersten Schweizer Tests zur Biopsie-Entscheidung in der Prostatakrebs-Diagnostik

October 27, 2020

Verbesserte Prostatakrebsdiagnostik – Ein Überblick im Magazin der Schweizerischen Union für Labormedizin

June 25, 2020

Proteomedix appoints Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD as Medical Advisor

May 26, 2020

Analytical performance of Proclarix® verified

May 19, 2020

Proteomedix and Dynex® Technologies enter into strategic alliance to provide automated workflows for Proclarix®

May 12, 2020

Center for Laboratory Medicine St. Gallen is the first laboratory to offer Proclarix®

April 2, 2020

Proteomedix announces commercial launch of Proclarix® in Europe

February 26, 2020

New data from Proclarix together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis to be showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 11, 2020

Proteomedix appoints Helge Lubenow as new CEO

January 10, 2020

Proteomedix today announced the appointment of Prof. em. Dr. med. Thomas Cerny as new member of the Board of Directors.

April 10, 2019

New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis

November 9, 2018

ProteoMediX Raises CHF 5.2 million in Financing Round

August 27, 2018

Novel Biomarker Test Avoids Biopsies by Accurately Predicting High-Grade Prostate Cancer

April 13, 2018

New publication describes the development and clinical testing of ProteoMediX’ immunoassays for prostate cancer diagnosis

August 3, 2017